Umeclidinium bromide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Umeclidinium bromide" in English language version.

refsWebsite

Global rank English rank

2clincalc.com

3,912^th place

2,496^th place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1web.archive.org

1^st place

1gsksource.com

low place

1doi.org

2^nd place

1nih.gov

4^th place

1semanticscholar.org

11^th place

8^th place

1medscape.com

719^th place

636^th place

1fda.gov

447^th place

338^th place

1handle.net

102^nd place

76^th place

canada.ca

"Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.

clincalc.com

"The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
"Umeclidinium - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

doi.org

Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.

fda.gov

accessdata.fda.gov

"TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Retrieved 11 July 2020.

gsksource.com

"Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Archived from the original (PDF) on 10 July 2018. Retrieved 22 February 2016.

handle.net

hdl.handle.net

World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

medscape.com

"FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.

nih.gov

pubmed.ncbi.nlm.nih.gov

Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.

semanticscholar.org

api.semanticscholar.org

Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

web.archive.org

"Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Archived from the original (PDF) on 10 July 2018. Retrieved 22 February 2016.